Roche × Rona Therapeutics
Rona Therapeutics granted Roche an exclusive worldwide license to its experimental RNAi therapy candidate targeting ALK7, a protein linked to obesity. The deal structure includes up to $100 million in upfront and near-term milestone payments. Rona is also eligible for up to $1.06 billion in potential development, regulatory, and commercial milestones, plus tiered royalties on global net sales.
The asset
An exclusive worldwide license for an investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) for the treatment of obesity and metabolic diseases.
The record
- Seller status
- Going concern
- Sector
- biotechnology
- Modalities
- biologic candidates, platform technology
What it means if you hold data
This transaction shows continued high-value investment in novel mechanisms for metabolic diseases, moving beyond established pathways. It validates the licensing of preclinical assets and their underlying data/delivery platforms as a key funding model for specialized biotech firms.